August 12, 2010 / 11:41 AM / 7 years ago

UPDATE 1-Aeterna Zentaris loss narrows on lower R&D costs

* Net loss 6 cents a share vs net loss 24 cents a year ago

* Revenue $5.6 million vs. $8.4 million (In U.S. dollars unless noted)

TORONTO, Aug 12 (Reuters) - Drugmaker Aeterna Zentaris Inc AEZ.TO posted a smaller quarterly loss on Thursday, attributed to lower research and development costs and higher foreign exchange gains.

Aeterna, known for its cancer drugs, reported a second- quarter loss of $4.5 million, or 6 cents a share, compared with a loss of $13.1 million, or 24 cents a share, for the same period a year ago.

Analysts had expected a loss of 10 cents a share, according to Thomson Reuters I/B/E/S.

Revenue fell to $5.6 million for the period that ended June 30, from $8.4 million last year.

The Quebec City-based company has about $45.3 million cash and cash equivalents on hand. ($1=$1.05 Canadian) (Reporting by Solarina Ho, editing by Maureen Bavdek)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below